These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study].
    Author: Chen J, Wu DP, Chen F, Zhao Y, Sun AN, Qiu HY.
    Journal: Zhonghua Yi Xue Za Zhi; 2013 Feb 26; 93(8):583-7. PubMed ID: 23663336.
    Abstract:
    OBJECTIVE: To compare the efficacies of hematopoietic stem cell transplantation with and without imatinib in the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia by evaluating the post-transplantation survival and quality-of-life. METHODS: A total of 35 acute lymphoblastic leukemia patients with Philadelphia chromosome-positive underwent hematopoietic stem cell transplantation from 2003 to 2011. They were divided into the imatinib (n = 23) and control (n = 12) groups. The incidence of graft-versus-host disease (GVHD), overall survival (OS), disease-free survival (DFS) and non-relapse mortality (NRM) of two groups were compared to identify the superiority of combined treatment. RESULTS: Age, gender, cytogenetic classification, donor type, proposed regimen and counts of infused stem cells were comparable between two groups. The proportion of patients in the first remission (CR1) in the imatinib group was higher than that in control group (20/23 vs 6/12, P = 0.038). However, single factor analysis showed that it did not affect the survival significantly (P = 0.884, 0.924). The estimated incidence of acute GVHD was 45.5% in the imatinib group versus 66.7% in the control group (P = 0.386). And the incidence of acute GVHD of Grades II-IV were 26.1% and 41.7% (P = 0.349) respectively. The estimated 5-year OS of two groups showed statistical difference (62.6% vs 41.7%, P = 0.028) and estimated 5-year DFS were 53.7% and 33.3% respectively (P = 0.054). The 5-year NRM was 41.7% in the control group and the main causes were infection and severe GVHD versus 22.7% in the imatinib group (P = 0.084) and the main cause was infection. The engraftment of white blood cell (median time: 13 vs 11 days, P = 0.008) and platelet (median time: 14 vs 11 days, P = 0.002) was delayed in imatinib group compared with control group. CONCLUSIONS: The patients of Philadelphia chromosome-positive acute lymphoblastic leukemia may acquire a better survival from the combined regimen of hematopoietic stem cell transplantation and imatinib, without increasing the hazard of acute GVHD and NRM.
    [Abstract] [Full Text] [Related] [New Search]